peginterferon alfa-2b + entecavir

A combination therapy consisting of peginterferon alfa-2b and entecavir used primarily for the treatment of chronic hepatitis B virus (HBV) infection. Peginterferon alfa-2b is a pegylated form of interferon with dual immunomodulatory and antiviral properties, while entecavir is a nucleoside analogue that selectively inhibits HBV polymerase. This combination aims to achieve better virological response and reduction of intrahepatic covalently closed circular DNA (cccDNA) compared to monotherapy. ## Peginterferon alfa-2b Peginterferon alfa-2b is a pegylated form of interferon alfa-2b, created by attaching a polyethylene glycol molecule to interferon alfa-2b. This modification improves the pharmacokinetic profile, allowing for once-weekly dosing instead of multiple injections per week required with standard interferon[5]. It works through dual immunomodulatory and antiviral mechanisms[5]. ## Entecavir Entecavir is a nucleoside analogue that selectively inhibits HBV polymerase. It functions by competing with the natural substrate deoxyguanosine triphosphate and inhibits all three activities of the HBV polymerase: base priming, reverse transcription of the negative strand from pregenomic messenger RNA, and synthesis of the positive strand of HBV DNA[6]. Upon activation by kinases, entecavir can be incorporated into DNA, ultimately inhibiting HBV polymerase activity[6].